Ustar Biotechnologies (Hangzhou) Ltd.
PrivateLast Round
Series E
Extension
Nov 30, 2021
Total Funding Raised
$78M
Company Overview
Ustar Biotechnologies (Hangzhou) Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series E Extension round in November 2021.
Ustar Biotechnologies (Hangzhou) Ltd. is a life sciences company that develops and manufactures innovative point-of-care molecular diagnostic instruments and test kits for infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ustar Biotechnologies (Hangzhou) Ltd. Comparables
Compare Ustar Biotechnologies (Hangzhou) Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Guangzhou Pluslife Biotech Co., Ltd. | 89% | |
| Igenesis | 85% | |
| Molbio Diagnostics | 84% |
For institutional investors. Book with your work email.
Ustar Biotechnologies (Hangzhou) Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E Extension | Nov 30, 2021 | ||||
| Series E | Feb 19, 2021 | ||||
| Series D | Jun 27, 2018 |
For institutional investors. Book with your work email.
Ustar Biotechnologies (Hangzhou) Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriental Fortune Capital | Series E Extension, Series E |
| Cenova Capital | Series E |
| CPE | Series E Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 30, 2021
$47M round led by CPE
- Feb 19, 2021
$31M round led by Oriental Fortune Capital
For institutional investors. Book with your work email.
Ustar Biotechnologies (Hangzhou) Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ustar Biotechnologies (Hangzhou) Ltd.'s valuation, stock price, and market status.
Is Ustar Biotechnologies (Hangzhou) Ltd. a public or private company?
Ustar Biotechnologies (Hangzhou) Ltd. is a private company.
What is the current stock price of Ustar Biotechnologies (Hangzhou) Ltd.?
Ustar Biotechnologies (Hangzhou) Ltd. is a private company, so its shares have no public market price. Caplight tracks Ustar Biotechnologies (Hangzhou) Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ustar Biotechnologies (Hangzhou) Ltd. worth (valuation)?
Valuation information for Ustar Biotechnologies (Hangzhou) Ltd. is not publicly available.
Can I buy Ustar Biotechnologies (Hangzhou) Ltd. stock?
Ustar Biotechnologies (Hangzhou) Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ustar Biotechnologies (Hangzhou) Ltd.'s last funding round?
Ustar Biotechnologies (Hangzhou) Ltd.'s most recent funding round was Series E Extension on November 30, 2021.
Who are the main investors in Ustar Biotechnologies (Hangzhou) Ltd.?
Key investors in Ustar Biotechnologies (Hangzhou) Ltd. include Oriental Fortune Capital, CPE.
Will Ustar Biotechnologies (Hangzhou) Ltd. IPO soon?
No public IPO plans have been announced for Ustar Biotechnologies (Hangzhou) Ltd..
How can I track Ustar Biotechnologies (Hangzhou) Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Ustar Biotechnologies (Hangzhou) Ltd.'s shares on secondary markets.